BioAdvance

Palvella Therapeutics is a biopharmaceutical company founded in 2015 and headquartered in Wayne, Pennsylvania. The company focuses on developing pathogenetically targeted therapies for serious and rare genetic skin diseases that lack approved treatments. Its lead candidate, QTORIN 3.9 % rapamycin anhydrous gel, is built on a patented QTORIN platform and is in late‑stage clinical development for two rare genodermatoses. Palvella’s approach emphasizes addressing the root cause of disease and delivering stable, room‑temperature formulations that penetrate the epidermis and dermis.

Founded in Philadelphia in 2018, Innervace is a regenerative therapy company focused on developing implantable tissue-engineered brain pathways for neurodegenerative disorders. Its lead product is a tissue-engineered nigrostriatal pathway designed to mimic the lost pathway in Parkinson's patients, providing potential disease-modifying therapies.

Founded in 2018, Phrase Health specializes in healthcare software solutions. Based in Philadelphia, Pennsylvania, the company helps hospitals monitor and analyze information provided to doctors and nurses at the point of care, enabling data-driven process improvements.

Palvella Therapeutics is a biopharmaceutical company founded in 2015 and headquartered in Wayne, Pennsylvania. The company focuses on developing pathogenetically targeted therapies for serious and rare genetic skin diseases that lack approved treatments. Its lead candidate, QTORIN 3.9 % rapamycin anhydrous gel, is built on a patented QTORIN platform and is in late‑stage clinical development for two rare genodermatoses. Palvella’s approach emphasizes addressing the root cause of disease and delivering stable, room‑temperature formulations that penetrate the epidermis and dermis.

Renovacor, Inc., established in 2013 and headquartered in Philadelphia, Pennsylvania, is a biopharmaceutical company dedicated to developing transformative gene therapies for cardiovascular diseases. Currently in the preclinical stage, Renovacor's primary focus is on creating a recombinant adeno-associated virus (AAV)-based gene therapy targeting patients with dilated cardiomyopathy (DCM) caused by mutations in the Bcl2-associated athanogene 3 (BAG3) gene. This condition affects approximately 35,000 individuals in the United States and Europe, qualifying it as an orphan disease. Renovacor aims to improve patient outcomes by potentially preventing disease progression through a BAG3 gene replacement therapy, given the current five-year survival rate of only 50% for DCM patients despite standard care.

Founded in 2018, Phrase Health specializes in healthcare software solutions. Based in Philadelphia, Pennsylvania, the company helps hospitals monitor and analyze information provided to doctors and nurses at the point of care, enabling data-driven process improvements.

Bainbridge Health, Inc. is a Philadelphia-based company founded in 2016 that specializes in developing a clinical intelligence and data analytics platform aimed at enhancing medication safety in hospital settings. The company's offerings include a vendor-agnostic medication safety platform that streamlines data management, reducing the reliance on manual data clerking and ad-hoc reporting. Their solutions, designed for medication safety leaders and hospital safety professionals, include an infusion pump management software known as InfusionWare, which centralizes infusion data to improve patient safety and effectively manage pump information. By mitigating medication errors, Bainbridge Health's platform helps healthcare providers reduce avoidable costs and improve overall patient care.

Opsidio is a biotechnology company specializing in the development of monoclonal antibodies for treating fibrotic and remodeling diseases. Founded in 2012, it is headquartered in Bryn Mawr, Pennsylvania.

Oncora Medical, Inc. is a digital health company based in Philadelphia, Pennsylvania, that develops an analytics platform specifically for radiation oncology. Founded in 2014, Oncora's software integrates data from various sources, including electronic medical records and treatment planning systems, to create a comprehensive database. This platform empowers radiation oncologists to use historical data and predictive analytics to make personalized treatment recommendations for cancer patients. Additionally, Oncora enables the application of machine learning algorithms to analyze patient outcomes, facilitating improved decision-making in cancer care. The company aims to enhance the effectiveness of radiation treatments by providing advanced reporting tools that unify and streamline access to critical oncology data.

CytoVas LLC is a life science company based in Philadelphia, Pennsylvania, that specializes in developing an innovative informatics platform called CLOUD CYTOMICS. This platform is designed to analyze flow cytometry data, providing clinicians and drug developers with actionable insights into novel cellular markers related to disease progression and individual treatment responses. CLOUD CYTOMICS automates the collection, mining, and modeling of data, facilitating the rapid identification and interpretation of cellular biomarkers. The technology is applicable across various therapeutic areas and disease states, including cardiovascular disease, type 2 diabetes, and Alzheimer's, and supports all stages of drug development. Founded in 2010 by experts in computational biology and flow cytometry, CytoVas is supported by significant investments from reputable organizations and maintains partnerships with leading entities in the field.

Olive Devices LLC is an assistive device company based in Philadelphia, Pennsylvania, that specializes in designing and developing smart glasses aimed at enhancing communication for individuals who are deaf or hard of hearing, as well as those with attention deficit disorders and early onset Alzheimer’s. The smart glasses feature real-time speech-to-text captions that appear in front of the user's eyes, facilitating better understanding and engagement. In addition to the glasses, Olive Devices offers a mobile application that supports personalized education by syncing captions to the cloud, allowing users to organize and select relevant information for note-taking and studying. The application also includes features that transform notes into memory games and study tools, as well as facilitate communication with teachers. Founded in 2015, Olive Devices provides its innovative solutions to a diverse range of users, including teachers, students, parents, audiologists, and optometrists.

Genome Profiling, LLC is a bioinformatics company based in Wayne, Pennsylvania, focused on the discovery of novel epigenetic biomarkers for diagnosing, treating, and predicting chronic and life-threatening diseases. Founded in 2012, the company has developed GenPro Analytics, an innovative software platform that enhances the ability of scientists and medical professionals to predict, diagnose, and monitor disease progression with improved sensitivity, specificity, accuracy, and cost-effectiveness. Genome Profiling offers a unique epigenetic biomarker discovery platform that integrates a proprietary pre-NGS gDNA preparation kit with advanced NGS data analytics algorithms, allowing for efficient incorporation into standard NGS workflows. This technology enables a single NGS run to yield comprehensive genomic variant call analyses alongside epigenetic data, positioning Genome Profiling at the forefront of the rapidly emerging market in genomic and epigenetic research.

Palvella Therapeutics is a biopharmaceutical company founded in 2015 and headquartered in Wayne, Pennsylvania. The company focuses on developing pathogenetically targeted therapies for serious and rare genetic skin diseases that lack approved treatments. Its lead candidate, QTORIN 3.9 % rapamycin anhydrous gel, is built on a patented QTORIN platform and is in late‑stage clinical development for two rare genodermatoses. Palvella’s approach emphasizes addressing the root cause of disease and delivering stable, room‑temperature formulations that penetrate the epidermis and dermis.

TalexMedical, LLC is a medical device company based in Philadelphia, Pennsylvania, that specializes in developing and manufacturing innovative solutions for treating external ear deformities in newborns. The company's flagship product, Infantear, is a Class I medical device designed as a nonsurgical ear molding system that can be applied in an outpatient setting, effectively replacing traditional surgical procedures. Infantear is customizable and constructed from soft materials, ensuring comfort for infants. This device allows pediatricians to address ear anomalies with a straightforward two-week treatment during the critical first three weeks of life, thereby reducing the need for costly and time-consuming referrals to specialists. Established in 2015, TalexMedical focuses on improving healthcare outcomes while enhancing patient satisfaction and minimizing costs.

VenatoRx Pharmaceuticals is a biopharmaceutical company dedicated to discovering and developing novel anti-infective agents. Established in 2010, the company focuses on addressing multi-drug resistant bacterial infections, including those caused by MRSA, Pseudomonas spp., and Salmonella spp.

Keriton provides a digital platform for managing inpatient feeding, focusing on patient safety and improving nursing workflows. Its system tracks milk-bottle inventory, recipes, feeding orders, expiry dates, and more from mobile devices. It also offers a media-sharing platform for nurses to connect NICU babies with their mothers and delivers real-time insights into milk production patterns.

Mebias Discovery, LLC is a pharmaceutical company focused on the discovery and development of pathway-selective drugs targeting G-protein coupled receptors (GPCRs). Founded in 2015 and headquartered in Philadelphia, Pennsylvania, the company aims to identify innovative molecules that bind to GPCRs, thereby minimizing on-target side effects traditionally associated with drug therapies. Mebias Discovery's technology emphasizes validated drug discovery methods, offering a robust platform that reduces the risks typically associated with exploring new therapeutic mechanisms. The company's research primarily targets neurodegenerative disorders, mood disorders, non-opioid pain management, cardiovascular conditions, and immuno-oncology, presenting significant opportunities for healthcare providers to address various diseases with improved therapeutic profiles.

Genome Profiling, LLC is a bioinformatics company based in Wayne, Pennsylvania, focused on the discovery of novel epigenetic biomarkers for diagnosing, treating, and predicting chronic and life-threatening diseases. Founded in 2012, the company has developed GenPro Analytics, an innovative software platform that enhances the ability of scientists and medical professionals to predict, diagnose, and monitor disease progression with improved sensitivity, specificity, accuracy, and cost-effectiveness. Genome Profiling offers a unique epigenetic biomarker discovery platform that integrates a proprietary pre-NGS gDNA preparation kit with advanced NGS data analytics algorithms, allowing for efficient incorporation into standard NGS workflows. This technology enables a single NGS run to yield comprehensive genomic variant call analyses alongside epigenetic data, positioning Genome Profiling at the forefront of the rapidly emerging market in genomic and epigenetic research.

Immunome is a biotechnology company specializing in immunotherapy and antigen discovery. It uses proprietary platforms to discover novel antigens and patient-derived antibodies targeting those antigens, focusing on oncology and infectious diseases.

Mebias Discovery, LLC is a pharmaceutical company focused on the discovery and development of pathway-selective drugs targeting G-protein coupled receptors (GPCRs). Founded in 2015 and headquartered in Philadelphia, Pennsylvania, the company aims to identify innovative molecules that bind to GPCRs, thereby minimizing on-target side effects traditionally associated with drug therapies. Mebias Discovery's technology emphasizes validated drug discovery methods, offering a robust platform that reduces the risks typically associated with exploring new therapeutic mechanisms. The company's research primarily targets neurodegenerative disorders, mood disorders, non-opioid pain management, cardiovascular conditions, and immuno-oncology, presenting significant opportunities for healthcare providers to address various diseases with improved therapeutic profiles.

Jenrin Discovery develops small-molecule therapeutics for chronic diseases, with a focus on peripherally selective agents targeting peripheral tissues. Its research encompasses obesity, diabetes, NAFLD/NASH, and autoimmune/inflammatory disorders, aiming to improve efficacy and safety for metabolic and inflammatory conditions. Founded in 2004, the company is headquartered in Philadelphia, Pennsylvania.

Bainbridge Health, Inc. is a Philadelphia-based company founded in 2016 that specializes in developing a clinical intelligence and data analytics platform aimed at enhancing medication safety in hospital settings. The company's offerings include a vendor-agnostic medication safety platform that streamlines data management, reducing the reliance on manual data clerking and ad-hoc reporting. Their solutions, designed for medication safety leaders and hospital safety professionals, include an infusion pump management software known as InfusionWare, which centralizes infusion data to improve patient safety and effectively manage pump information. By mitigating medication errors, Bainbridge Health's platform helps healthcare providers reduce avoidable costs and improve overall patient care.

Enzium, Inc. specializes in the development and marketing of fluorescence-based reagents for the detection of protease activity. Founded in 2011 and based in Pittsburgh, Pennsylvania, the company offers a range of protease activity sensors utilized in the diagnostic and life science industries, including assays for caspases, matrix metalloproteinases, and microbial proteases. Enzium's proprietary modular technology allows for the rapid customization of assay reagents by swapping protein modules, akin to building with Legos. This innovative approach enables their customers, spanning pharmaceutical, biotech, contract research organizations, academia, and government sectors, to seamlessly integrate their reagents into various applications throughout research, drug development, and diagnostic pipelines.

Olive Devices LLC is an assistive device company based in Philadelphia, Pennsylvania, that specializes in designing and developing smart glasses aimed at enhancing communication for individuals who are deaf or hard of hearing, as well as those with attention deficit disorders and early onset Alzheimer’s. The smart glasses feature real-time speech-to-text captions that appear in front of the user's eyes, facilitating better understanding and engagement. In addition to the glasses, Olive Devices offers a mobile application that supports personalized education by syncing captions to the cloud, allowing users to organize and select relevant information for note-taking and studying. The application also includes features that transform notes into memory games and study tools, as well as facilitate communication with teachers. Founded in 2015, Olive Devices provides its innovative solutions to a diverse range of users, including teachers, students, parents, audiologists, and optometrists.

Penn State Health is a multi-hospital health system based in Central Pennsylvania, distinguished as the region's only academic medical center. It operates the Milton S. Hershey Medical Center, a 551-bed Level I regional trauma center, which includes the Children's Hospital and is affiliated with the Penn State College of Medicine. The system is recognized for its capability to handle complex adult and pediatric cases, reflecting its commitment to high-quality patient care. Additionally, Penn State Health has achieved ANCC Magnet Recognition, underscoring its dedication to fostering a professional environment that promotes staff development and enhances the overall patient experience.

Noble.MD is a healthcare technology company based in Bryn Mawr, Pennsylvania, founded in 2012. It develops Theo, a digital healthcare advisory platform designed to identify health and behavioral risks for patients. The platform enables patients to actively manage these risks through tailored programs and interventions. By capturing essential patient data at the point of care, Noble.MD facilitates value-based reimbursement and aligns the interests of providers and payers, enhancing the processes of risk identification, coding, and management. Through its innovative approach, Noble.MD engages patients in understanding their symptoms, behaviors, and intentions, while encouraging actionable steps towards improved health outcomes.

Jenrin Discovery develops small-molecule therapeutics for chronic diseases, with a focus on peripherally selective agents targeting peripheral tissues. Its research encompasses obesity, diabetes, NAFLD/NASH, and autoimmune/inflammatory disorders, aiming to improve efficacy and safety for metabolic and inflammatory conditions. Founded in 2004, the company is headquartered in Philadelphia, Pennsylvania.

Oncora Medical, Inc. is a digital health company based in Philadelphia, Pennsylvania, that develops an analytics platform specifically for radiation oncology. Founded in 2014, Oncora's software integrates data from various sources, including electronic medical records and treatment planning systems, to create a comprehensive database. This platform empowers radiation oncologists to use historical data and predictive analytics to make personalized treatment recommendations for cancer patients. Additionally, Oncora enables the application of machine learning algorithms to analyze patient outcomes, facilitating improved decision-making in cancer care. The company aims to enhance the effectiveness of radiation treatments by providing advanced reporting tools that unify and streamline access to critical oncology data.

Mebias Discovery, LLC is a pharmaceutical company focused on the discovery and development of pathway-selective drugs targeting G-protein coupled receptors (GPCRs). Founded in 2015 and headquartered in Philadelphia, Pennsylvania, the company aims to identify innovative molecules that bind to GPCRs, thereby minimizing on-target side effects traditionally associated with drug therapies. Mebias Discovery's technology emphasizes validated drug discovery methods, offering a robust platform that reduces the risks typically associated with exploring new therapeutic mechanisms. The company's research primarily targets neurodegenerative disorders, mood disorders, non-opioid pain management, cardiovascular conditions, and immuno-oncology, presenting significant opportunities for healthcare providers to address various diseases with improved therapeutic profiles.

Enzium, Inc. specializes in the development and marketing of fluorescence-based reagents for the detection of protease activity. Founded in 2011 and based in Pittsburgh, Pennsylvania, the company offers a range of protease activity sensors utilized in the diagnostic and life science industries, including assays for caspases, matrix metalloproteinases, and microbial proteases. Enzium's proprietary modular technology allows for the rapid customization of assay reagents by swapping protein modules, akin to building with Legos. This innovative approach enables their customers, spanning pharmaceutical, biotech, contract research organizations, academia, and government sectors, to seamlessly integrate their reagents into various applications throughout research, drug development, and diagnostic pipelines.

RiboNova Inc. is a biopharmaceutical company based in Wynnewood, Pennsylvania, specializing in the development of small molecule drugs aimed at treating serious rare diseases, including mitochondrial disorders and certain types of cancer. Founded in 2011, RiboNova focuses on innovative therapies that target defective transfer RNAs and ribonucleic acid anomalies. The company's drug discovery platform is designed to create precision medicines that provide healthcare professionals with effective treatment options for patients suffering from these conditions. RiboNova operates within the Lankenau Institute for Medical Research, leveraging its research capabilities to advance its therapeutic pipeline.

Hsiri Therapeutics, LLC is a pharmaceutical company focused on the discovery and development of innovative antibiotics to address serious infectious diseases caused by drug-resistant bacteria. Founded in 2012 and based in Media, Pennsylvania, the company primarily targets mycobacterial diseases and gram-negative infections. Its product pipeline includes HT-01, a topical treatment for gram-positive infections; HT-02, designed for serious gram-positive infections; HT-03, an anti-mycobacterial agent for mycobacterium avium-intracellulare complex; HT-04, aimed at drug-resistant mycobacterium tuberculosis; and HT-05, a novel compound based on modified amino-penicillin structures. Hsiri Therapeutics also explores therapies for infections caused by acinetobacter and klebsiella. The company's research has its roots in the laboratories of Professor Marvin Miller at the University of Notre Dame, emphasizing a commitment to developing effective solutions for difficult-to-treat bacterial infections.

Enzium, Inc. specializes in the development and marketing of fluorescence-based reagents for the detection of protease activity. Founded in 2011 and based in Pittsburgh, Pennsylvania, the company offers a range of protease activity sensors utilized in the diagnostic and life science industries, including assays for caspases, matrix metalloproteinases, and microbial proteases. Enzium's proprietary modular technology allows for the rapid customization of assay reagents by swapping protein modules, akin to building with Legos. This innovative approach enables their customers, spanning pharmaceutical, biotech, contract research organizations, academia, and government sectors, to seamlessly integrate their reagents into various applications throughout research, drug development, and diagnostic pipelines.

CarePartners Plus is a technology-enabled health care communications, data, and software company founded in 2009 and based in Horsham, Pennsylvania. It offers Wellby, a cloud-based patient engagement platform that captures, analyzes, and shares patient-generated data in real time. The platform supports patient management, caregiver coordination, care coordination, and cost containment for hospitals, physician groups, insurers, employers, and other stakeholders. It serves a broad range of clients including hospitals, medical groups, insurers, employers, government agencies, public health organizations, accreditation bodies, educators, researchers, and patients. The company focuses on improving patient experience, compliance, and outcomes through evidence-based engagement programs.

Allevi is a pioneering company that develops innovative tools for designing and engineering 3D tissues. It specializes in desktop 3D bioprinters capable of creating functional, three-dimensional living tissues, alongside proprietary bioinks composed of collagen and hyaluronic acid. Allevi's cloud-based platform, Bioprint Online, allows users to design structures, select materials, and monitor the printing process. Its products cater to a diverse clientele, including researchers in tissue engineering, regenerative medicine, material science, and cell biology, as well as industrial and pharmaceutical companies involved in drug testing and development. Additionally, Allevi sells its bioinks online. Founded in 2014 and headquartered in Philadelphia, Pennsylvania, the company was previously known as BioBots, Inc.

Galleon Pharmaceuticals, Inc. is a pharmaceutical company based in Horsham, Pennsylvania, focused on discovering and developing innovative treatments for sleep apnea and related breathing control disorders. Established in 2003, the company is engaged in creating a portfolio of therapeutics aimed at addressing a variety of respiratory conditions, including sleep apnea, ventilator weaning, anesthetic-induced respiratory depression, chronic obstructive pulmonary disease (COPD), and obesity-hypoventilation syndrome. Among its key offerings are GAL-021, an intravenous small molecule that supports respiratory drive in surgical and critical care patients, GLN-21,160, an oral candidate for sleep apnea, and GAL-044, which serves as a preventative medication for surgical pain. Galleon Pharmaceuticals is committed to enhancing patient care through its neuro-respiratory drug development initiatives.

Enzium, Inc. specializes in the development and marketing of fluorescence-based reagents for the detection of protease activity. Founded in 2011 and based in Pittsburgh, Pennsylvania, the company offers a range of protease activity sensors utilized in the diagnostic and life science industries, including assays for caspases, matrix metalloproteinases, and microbial proteases. Enzium's proprietary modular technology allows for the rapid customization of assay reagents by swapping protein modules, akin to building with Legos. This innovative approach enables their customers, spanning pharmaceutical, biotech, contract research organizations, academia, and government sectors, to seamlessly integrate their reagents into various applications throughout research, drug development, and diagnostic pipelines.

HealthQx, established in 2012 and headquartered in King of Prussia, Pennsylvania, specializes in Value-based Payment (VBP) analytic software solutions for health plans and providers. Its flagship product, ClarityQx, empowers users to design, implement, and monitor the performance of alternative payment models such as episodic or bundled arrangements. The platform facilitates provider engagement and contract negotiation processes, aiming to enhance consumer care while reducing medical costs.

TowerView helps the 1 in 3 Americans with a chronic illness manage multiple medications. TowerView’s patients receive pre-filled medication trays that fit into a connected pillbox like a K-Cup into a Keurig coffee machine. Their pillbox can sense when patients forget a dose and automatically sends a text or phone reminder. Unlike other smart pillboxes, they send patients pre-filled medication trays sourced from a pharmacy so patients never have to fill their own pillbox and they work directly with nurses​ to target outreach for non-adherent patients. TowerView is rolling out with Independence Blue Cross in January 2015 and are in advanced discussions with numerous other health plans.

Jenrin Discovery develops small-molecule therapeutics for chronic diseases, with a focus on peripherally selective agents targeting peripheral tissues. Its research encompasses obesity, diabetes, NAFLD/NASH, and autoimmune/inflammatory disorders, aiming to improve efficacy and safety for metabolic and inflammatory conditions. Founded in 2004, the company is headquartered in Philadelphia, Pennsylvania.

Merganser Biotech, Inc. is a biotechnology company focused on developing innovative medicines for rare hematological and iron overload diseases, including hemochromatosis, polycythemia vera, and beta thalassemia. Established in 2011 and headquartered in King of Prussia, Pennsylvania, the company specializes in creating hepcidin mimetic peptides aimed at regulating iron metabolism and addressing ineffective erythropoiesis. Through its research and development efforts, Merganser Biotech strives to provide effective treatments that enhance patient outcomes in the management of these complex conditions.

Hsiri Therapeutics, LLC is a pharmaceutical company focused on the discovery and development of innovative antibiotics to address serious infectious diseases caused by drug-resistant bacteria. Founded in 2012 and based in Media, Pennsylvania, the company primarily targets mycobacterial diseases and gram-negative infections. Its product pipeline includes HT-01, a topical treatment for gram-positive infections; HT-02, designed for serious gram-positive infections; HT-03, an anti-mycobacterial agent for mycobacterium avium-intracellulare complex; HT-04, aimed at drug-resistant mycobacterium tuberculosis; and HT-05, a novel compound based on modified amino-penicillin structures. Hsiri Therapeutics also explores therapies for infections caused by acinetobacter and klebsiella. The company's research has its roots in the laboratories of Professor Marvin Miller at the University of Notre Dame, emphasizing a commitment to developing effective solutions for difficult-to-treat bacterial infections.

Novira Therapeutics is a clinical‑stage biopharmaceutical company that discovers and develops oral antiviral drugs targeting the capsid of hepatitis B virus and human immunodeficiency virus. Its pipeline focuses on first‑in‑class capsid inhibitors that can be used alone or with existing therapies, aiming to overcome limitations of current polymerase inhibitors and drug‑resistant HIV strains. The company was founded in 2006 as Molecmo Nanobiotechnologies and is headquartered in Doylestown, Pennsylvania. It has pursued partnerships and collaborations to advance its candidates toward clinical evaluation.

Ossianix Inc. is a biotherapeutics company that specializes in developing single domain antibodies derived from the VNAR structure of sharks. Founded in 2012 and headquartered in Philadelphia, Pennsylvania, with research facilities in Stevenage, United Kingdom, Ossianix utilizes its VNAR platform to create high-affinity products that address various therapeutic targets. This innovative approach allows for the rapid development of bispecific and trispecific antibodies, which can be tailored for specific clinical applications, including targeting the blood-brain barrier and gastrointestinal tract. The company has also established a strategic research collaboration with Lundbeck A/S to advance its drug discovery programs across different therapeutic areas.

Immunome is a biotechnology company specializing in immunotherapy and antigen discovery. It uses proprietary platforms to discover novel antigens and patient-derived antibodies targeting those antigens, focusing on oncology and infectious diseases.

Jenrin Discovery develops small-molecule therapeutics for chronic diseases, with a focus on peripherally selective agents targeting peripheral tissues. Its research encompasses obesity, diabetes, NAFLD/NASH, and autoimmune/inflammatory disorders, aiming to improve efficacy and safety for metabolic and inflammatory conditions. Founded in 2004, the company is headquartered in Philadelphia, Pennsylvania.

HealthQx, established in 2012 and headquartered in King of Prussia, Pennsylvania, specializes in Value-based Payment (VBP) analytic software solutions for health plans and providers. Its flagship product, ClarityQx, empowers users to design, implement, and monitor the performance of alternative payment models such as episodic or bundled arrangements. The platform facilitates provider engagement and contract negotiation processes, aiming to enhance consumer care while reducing medical costs.

InfraScan, Inc. is a Philadelphia-based medical device company specializing in the development and commercialization of hand-held diagnostic devices that utilize near-infrared (NIR) technology for assessing head injuries and strokes. The company’s primary product, the Infrascanner, allows clinicians to accurately detect intracranial bleeding in patients experiencing head trauma, which is critical for preventing secondary brain injuries. The device is versatile and finds applications in various settings, including hospitals, military operations, remote screenings, sports medicine, pediatrics, and ambulance services. InfraScan, founded in 2004, collaborates with distributors across North America, South America, Africa, Asia, the Middle East, and Europe to reach a wide market. The company's innovative approach was pioneered by a team of researchers and has undergone extensive clinical testing, positioning InfraScan as a leader in the realm of emergency diagnostic tools.

Merganser Biotech, Inc. is a biotechnology company focused on developing innovative medicines for rare hematological and iron overload diseases, including hemochromatosis, polycythemia vera, and beta thalassemia. Established in 2011 and headquartered in King of Prussia, Pennsylvania, the company specializes in creating hepcidin mimetic peptides aimed at regulating iron metabolism and addressing ineffective erythropoiesis. Through its research and development efforts, Merganser Biotech strives to provide effective treatments that enhance patient outcomes in the management of these complex conditions.

VenatoRx Pharmaceuticals is a biopharmaceutical company dedicated to discovering and developing novel anti-infective agents. Established in 2010, the company focuses on addressing multi-drug resistant bacterial infections, including those caused by MRSA, Pseudomonas spp., and Salmonella spp.

Immunome is a biotechnology company specializing in immunotherapy and antigen discovery. It uses proprietary platforms to discover novel antigens and patient-derived antibodies targeting those antigens, focusing on oncology and infectious diseases.

Annovis Bio is a clinical-stage pharmaceutical company focused on developing drugs to treat neurodegenerative disorders. Its lead compound, ANVS401, is in Phase 2a trials for Alzheimer's and Parkinson's diseases. The company also develops ANVS405 for neuroprotection post-traumatic brain injury/stroke, and ANVS301 for cognitive enhancement in late-stage AD.

Ossianix Inc. is a biotherapeutics company that specializes in developing single domain antibodies derived from the VNAR structure of sharks. Founded in 2012 and headquartered in Philadelphia, Pennsylvania, with research facilities in Stevenage, United Kingdom, Ossianix utilizes its VNAR platform to create high-affinity products that address various therapeutic targets. This innovative approach allows for the rapid development of bispecific and trispecific antibodies, which can be tailored for specific clinical applications, including targeting the blood-brain barrier and gastrointestinal tract. The company has also established a strategic research collaboration with Lundbeck A/S to advance its drug discovery programs across different therapeutic areas.

Enzium, Inc. specializes in the development and marketing of fluorescence-based reagents for the detection of protease activity. Founded in 2011 and based in Pittsburgh, Pennsylvania, the company offers a range of protease activity sensors utilized in the diagnostic and life science industries, including assays for caspases, matrix metalloproteinases, and microbial proteases. Enzium's proprietary modular technology allows for the rapid customization of assay reagents by swapping protein modules, akin to building with Legos. This innovative approach enables their customers, spanning pharmaceutical, biotech, contract research organizations, academia, and government sectors, to seamlessly integrate their reagents into various applications throughout research, drug development, and diagnostic pipelines.

Merganser Biotech, Inc. is a biotechnology company focused on developing innovative medicines for rare hematological and iron overload diseases, including hemochromatosis, polycythemia vera, and beta thalassemia. Established in 2011 and headquartered in King of Prussia, Pennsylvania, the company specializes in creating hepcidin mimetic peptides aimed at regulating iron metabolism and addressing ineffective erythropoiesis. Through its research and development efforts, Merganser Biotech strives to provide effective treatments that enhance patient outcomes in the management of these complex conditions.

Novira Therapeutics is a clinical‑stage biopharmaceutical company that discovers and develops oral antiviral drugs targeting the capsid of hepatitis B virus and human immunodeficiency virus. Its pipeline focuses on first‑in‑class capsid inhibitors that can be used alone or with existing therapies, aiming to overcome limitations of current polymerase inhibitors and drug‑resistant HIV strains. The company was founded in 2006 as Molecmo Nanobiotechnologies and is headquartered in Doylestown, Pennsylvania. It has pursued partnerships and collaborations to advance its candidates toward clinical evaluation.

Immunome is a biotechnology company specializing in immunotherapy and antigen discovery. It uses proprietary platforms to discover novel antigens and patient-derived antibodies targeting those antigens, focusing on oncology and infectious diseases.

Life Mist Technologies, Inc., based in Paoli, Pennsylvania, specializes in the development and commercialization of advanced atomization technology that generates high volumes of micron-sized droplets using low-pressure gas and liquid. Founded in 2004, the company applies its innovative technology across a diverse range of industrial applications, including aircraft fire suppression, chemical processing, emission control, and decontamination. Additionally, their technology is utilized for turbine inlet cooling and the production of artificial snow. By enhancing existing processes, Life Mist Technologies aims to address various challenges faced by industries that require effective solutions for fire suppression, cooling, and pathogen control.

Jenrin Discovery develops small-molecule therapeutics for chronic diseases, with a focus on peripherally selective agents targeting peripheral tissues. Its research encompasses obesity, diabetes, NAFLD/NASH, and autoimmune/inflammatory disorders, aiming to improve efficacy and safety for metabolic and inflammatory conditions. Founded in 2004, the company is headquartered in Philadelphia, Pennsylvania.

Merganser Biotech, Inc. is a biotechnology company focused on developing innovative medicines for rare hematological and iron overload diseases, including hemochromatosis, polycythemia vera, and beta thalassemia. Established in 2011 and headquartered in King of Prussia, Pennsylvania, the company specializes in creating hepcidin mimetic peptides aimed at regulating iron metabolism and addressing ineffective erythropoiesis. Through its research and development efforts, Merganser Biotech strives to provide effective treatments that enhance patient outcomes in the management of these complex conditions.

Innovative Supply Solutions LLC is a specialty contract service organization based in Southampton, Pennsylvania, that specializes in clinical drug supply chain management. The company offers a comprehensive range of services, including planning and forecasting for active pharmaceutical ingredients and formulated products, project management, budget management, packaging design, and inventory management. Additionally, it coordinates supply chain activities such as manufacturing, packaging, labeling, and distribution, as well as providing analytical services and consultancy. Since its inception in 2010, Innovative Supply Solutions has developed proprietary software that enhances the efficiency and effectiveness of supply chain management, enabling healthcare providers to mitigate risks associated with clinical trials while achieving cost savings and precise results. The company’s tailored solutions and proven technology allow for significant accuracy in forecasting, ensuring that variances remain under 10%.

Innovative Supply Solutions LLC is a specialty contract service organization based in Southampton, Pennsylvania, that specializes in clinical drug supply chain management. The company offers a comprehensive range of services, including planning and forecasting for active pharmaceutical ingredients and formulated products, project management, budget management, packaging design, and inventory management. Additionally, it coordinates supply chain activities such as manufacturing, packaging, labeling, and distribution, as well as providing analytical services and consultancy. Since its inception in 2010, Innovative Supply Solutions has developed proprietary software that enhances the efficiency and effectiveness of supply chain management, enabling healthcare providers to mitigate risks associated with clinical trials while achieving cost savings and precise results. The company’s tailored solutions and proven technology allow for significant accuracy in forecasting, ensuring that variances remain under 10%.

Melior Discovery, Inc. is a biotechnology company based in Exton, Pennsylvania, specializing in developing an in vivo pharmacology platform aimed at identifying novel therapeutic applications for pre-clinical and development-stage drug candidates. Founded in 2005, the company utilizes its innovative theraTRACE indications discovery platform, which systematically evaluates a single compound across multiple in vivo models. This approach enables Melior to assess the potential utility of drug candidates in various therapeutic areas, including neurodegenerative diseases, inflammation, pain management, metabolic disorders, gastrointestinal issues, cardiovascular diseases, and dermatology. Melior Discovery primarily serves clients in the pharmaceutical and biopharmaceutical industries, offering rapid and cost-effective solutions for identifying new therapeutic potentials of existing drugs.

Imiplex LLC is a biotechnology company based in Bristol, Pennsylvania, founded in 2003. The company specializes in developing engineered protein nanostructures for various applications, including targeted therapeutics, biosensors, and functional biomaterials. Implex's technology leverages the unique properties of proteins, such as their ability to self-assemble with atomic precision and their structural diversity. This allows for the creation of a reusable system for constructing diverse nanostructures, which can be used in early disease diagnosis, including cancer, diabetes, Alzheimer's disease, and other neurodegenerative conditions.

CarePartners Plus is a technology-enabled health care communications, data, and software company founded in 2009 and based in Horsham, Pennsylvania. It offers Wellby, a cloud-based patient engagement platform that captures, analyzes, and shares patient-generated data in real time. The platform supports patient management, caregiver coordination, care coordination, and cost containment for hospitals, physician groups, insurers, employers, and other stakeholders. It serves a broad range of clients including hospitals, medical groups, insurers, employers, government agencies, public health organizations, accreditation bodies, educators, researchers, and patients. The company focuses on improving patient experience, compliance, and outcomes through evidence-based engagement programs.

Galleon Pharmaceuticals, Inc. is a pharmaceutical company based in Horsham, Pennsylvania, focused on discovering and developing innovative treatments for sleep apnea and related breathing control disorders. Established in 2003, the company is engaged in creating a portfolio of therapeutics aimed at addressing a variety of respiratory conditions, including sleep apnea, ventilator weaning, anesthetic-induced respiratory depression, chronic obstructive pulmonary disease (COPD), and obesity-hypoventilation syndrome. Among its key offerings are GAL-021, an intravenous small molecule that supports respiratory drive in surgical and critical care patients, GLN-21,160, an oral candidate for sleep apnea, and GAL-044, which serves as a preventative medication for surgical pain. Galleon Pharmaceuticals is committed to enhancing patient care through its neuro-respiratory drug development initiatives.

Immunome is a biotechnology company specializing in immunotherapy and antigen discovery. It uses proprietary platforms to discover novel antigens and patient-derived antibodies targeting those antigens, focusing on oncology and infectious diseases.

Melior Discovery, Inc. is a biotechnology company based in Exton, Pennsylvania, specializing in developing an in vivo pharmacology platform aimed at identifying novel therapeutic applications for pre-clinical and development-stage drug candidates. Founded in 2005, the company utilizes its innovative theraTRACE indications discovery platform, which systematically evaluates a single compound across multiple in vivo models. This approach enables Melior to assess the potential utility of drug candidates in various therapeutic areas, including neurodegenerative diseases, inflammation, pain management, metabolic disorders, gastrointestinal issues, cardiovascular diseases, and dermatology. Melior Discovery primarily serves clients in the pharmaceutical and biopharmaceutical industries, offering rapid and cost-effective solutions for identifying new therapeutic potentials of existing drugs.

Novira Therapeutics is a clinical‑stage biopharmaceutical company that discovers and develops oral antiviral drugs targeting the capsid of hepatitis B virus and human immunodeficiency virus. Its pipeline focuses on first‑in‑class capsid inhibitors that can be used alone or with existing therapies, aiming to overcome limitations of current polymerase inhibitors and drug‑resistant HIV strains. The company was founded in 2006 as Molecmo Nanobiotechnologies and is headquartered in Doylestown, Pennsylvania. It has pursued partnerships and collaborations to advance its candidates toward clinical evaluation.

Immunome is a biotechnology company specializing in immunotherapy and antigen discovery. It uses proprietary platforms to discover novel antigens and patient-derived antibodies targeting those antigens, focusing on oncology and infectious diseases.

Immunome is a biotechnology company specializing in immunotherapy and antigen discovery. It uses proprietary platforms to discover novel antigens and patient-derived antibodies targeting those antigens, focusing on oncology and infectious diseases.

Leversense, LLC intends to develop a medical device for detecting AIDS, food toxin, and mycoplasma bacteria. The company was incorporated in 2009 and is based in Newtown Square, Pennsylvania.

Jenrin Discovery develops small-molecule therapeutics for chronic diseases, with a focus on peripherally selective agents targeting peripheral tissues. Its research encompasses obesity, diabetes, NAFLD/NASH, and autoimmune/inflammatory disorders, aiming to improve efficacy and safety for metabolic and inflammatory conditions. Founded in 2004, the company is headquartered in Philadelphia, Pennsylvania.

Novira Therapeutics is a clinical‑stage biopharmaceutical company that discovers and develops oral antiviral drugs targeting the capsid of hepatitis B virus and human immunodeficiency virus. Its pipeline focuses on first‑in‑class capsid inhibitors that can be used alone or with existing therapies, aiming to overcome limitations of current polymerase inhibitors and drug‑resistant HIV strains. The company was founded in 2006 as Molecmo Nanobiotechnologies and is headquartered in Doylestown, Pennsylvania. It has pursued partnerships and collaborations to advance its candidates toward clinical evaluation.

Immunome is a biotechnology company specializing in immunotherapy and antigen discovery. It uses proprietary platforms to discover novel antigens and patient-derived antibodies targeting those antigens, focusing on oncology and infectious diseases.

Formae, Inc. is a company specializing in joint resurfacing technology, focusing on the development of innovative products for arthroscopic joint resurfacing and replacement. Founded in 2006 and based in Paoli, Pennsylvania, Formae has created a proprietary synthetic cartilage used in its biocompatible implant, known as ArthroPad. This implant provides a minimally invasive surgical option for replacing damaged cartilage in arthritic joints, addressing conditions such as arthritis and joint destruction. Through its advanced technology, Formae aims to improve patient outcomes in joint care.

Phoenix S&T, Inc. is a developer and supplier of advanced nanospray and microspray systems tailored for life science research and drug discovery. Founded in 2001, the company specializes in the design and production of micro-molded devices, including its Nimbus and pneu-Nimbus NanoLC systems, which facilitate ionization for various applications such as proteomics, biomarker analysis, and clinical diagnostics. Phoenix S&T's product offerings also include column heaters, column coolers, emitters, and 3D microfluidic devices, all engineered for seamless integration with existing mass spectrometers and high-throughput robotics. The company serves a diverse clientele across Europe and China, positioning itself as a key player in the fields of drug discovery and homeland security. With headquarters located in Chadds Ford, Pennsylvania, Phoenix S&T continues to innovate in the realm of microfluidics and analytical technology.

Novira Therapeutics is a clinical‑stage biopharmaceutical company that discovers and develops oral antiviral drugs targeting the capsid of hepatitis B virus and human immunodeficiency virus. Its pipeline focuses on first‑in‑class capsid inhibitors that can be used alone or with existing therapies, aiming to overcome limitations of current polymerase inhibitors and drug‑resistant HIV strains. The company was founded in 2006 as Molecmo Nanobiotechnologies and is headquartered in Doylestown, Pennsylvania. It has pursued partnerships and collaborations to advance its candidates toward clinical evaluation.

Novira Therapeutics is a clinical‑stage biopharmaceutical company that discovers and develops oral antiviral drugs targeting the capsid of hepatitis B virus and human immunodeficiency virus. Its pipeline focuses on first‑in‑class capsid inhibitors that can be used alone or with existing therapies, aiming to overcome limitations of current polymerase inhibitors and drug‑resistant HIV strains. The company was founded in 2006 as Molecmo Nanobiotechnologies and is headquartered in Doylestown, Pennsylvania. It has pursued partnerships and collaborations to advance its candidates toward clinical evaluation.

Annovis Bio is a clinical-stage pharmaceutical company focused on developing drugs to treat neurodegenerative disorders. Its lead compound, ANVS401, is in Phase 2a trials for Alzheimer's and Parkinson's diseases. The company also develops ANVS405 for neuroprotection post-traumatic brain injury/stroke, and ANVS301 for cognitive enhancement in late-stage AD.

Melior Discovery, Inc. is a biotechnology company based in Exton, Pennsylvania, specializing in developing an in vivo pharmacology platform aimed at identifying novel therapeutic applications for pre-clinical and development-stage drug candidates. Founded in 2005, the company utilizes its innovative theraTRACE indications discovery platform, which systematically evaluates a single compound across multiple in vivo models. This approach enables Melior to assess the potential utility of drug candidates in various therapeutic areas, including neurodegenerative diseases, inflammation, pain management, metabolic disorders, gastrointestinal issues, cardiovascular diseases, and dermatology. Melior Discovery primarily serves clients in the pharmaceutical and biopharmaceutical industries, offering rapid and cost-effective solutions for identifying new therapeutic potentials of existing drugs.

Innovative Supply Solutions LLC is a specialty contract service organization based in Southampton, Pennsylvania, that specializes in clinical drug supply chain management. The company offers a comprehensive range of services, including planning and forecasting for active pharmaceutical ingredients and formulated products, project management, budget management, packaging design, and inventory management. Additionally, it coordinates supply chain activities such as manufacturing, packaging, labeling, and distribution, as well as providing analytical services and consultancy. Since its inception in 2010, Innovative Supply Solutions has developed proprietary software that enhances the efficiency and effectiveness of supply chain management, enabling healthcare providers to mitigate risks associated with clinical trials while achieving cost savings and precise results. The company’s tailored solutions and proven technology allow for significant accuracy in forecasting, ensuring that variances remain under 10%.

Temple University, a prominent public research institution in Philadelphia, offers over 300 academic programs leading to bachelor’s, master’s, and doctoral degrees across various fields. Known for its professional education schools, Temple graduates many students as doctors, lawyers, dentists, architects, pharmacists, and more. Research is integral to the university's mission, with numerous research centers. Student life is vibrant, featuring over 200 student organizations, a newspaper, radio station, and arts entertainment opportunities.

Jenrin Discovery develops small-molecule therapeutics for chronic diseases, with a focus on peripherally selective agents targeting peripheral tissues. Its research encompasses obesity, diabetes, NAFLD/NASH, and autoimmune/inflammatory disorders, aiming to improve efficacy and safety for metabolic and inflammatory conditions. Founded in 2004, the company is headquartered in Philadelphia, Pennsylvania.

Novira Therapeutics is a clinical‑stage biopharmaceutical company that discovers and develops oral antiviral drugs targeting the capsid of hepatitis B virus and human immunodeficiency virus. Its pipeline focuses on first‑in‑class capsid inhibitors that can be used alone or with existing therapies, aiming to overcome limitations of current polymerase inhibitors and drug‑resistant HIV strains. The company was founded in 2006 as Molecmo Nanobiotechnologies and is headquartered in Doylestown, Pennsylvania. It has pursued partnerships and collaborations to advance its candidates toward clinical evaluation.

Immunome is a biotechnology company specializing in immunotherapy and antigen discovery. It uses proprietary platforms to discover novel antigens and patient-derived antibodies targeting those antigens, focusing on oncology and infectious diseases.

Avid Radiopharmaceuticals is a Philadelphia-based company focused on the development of molecular imaging agents designed to enhance the medical management of chronic diseases. Its mission centers on creating innovative imaging compounds that facilitate the early identification of pathological changes, thereby supporting earlier diagnosis and improved management of various conditions. Avid's notable product, Amyvid, is an imaging tool utilized in positron emission tomography to detect beta-amyloid plaques in the brain, which plays a crucial role in the assessment of Alzheimer's disease. Through its advancements in molecular imaging, Avid aims to contribute to the development of new therapies and improve clinical outcomes for patients suffering from significant chronic illnesses.

Novira Therapeutics is a clinical‑stage biopharmaceutical company that discovers and develops oral antiviral drugs targeting the capsid of hepatitis B virus and human immunodeficiency virus. Its pipeline focuses on first‑in‑class capsid inhibitors that can be used alone or with existing therapies, aiming to overcome limitations of current polymerase inhibitors and drug‑resistant HIV strains. The company was founded in 2006 as Molecmo Nanobiotechnologies and is headquartered in Doylestown, Pennsylvania. It has pursued partnerships and collaborations to advance its candidates toward clinical evaluation.

InfraScan, Inc. is a Philadelphia-based medical device company specializing in the development and commercialization of hand-held diagnostic devices that utilize near-infrared (NIR) technology for assessing head injuries and strokes. The company’s primary product, the Infrascanner, allows clinicians to accurately detect intracranial bleeding in patients experiencing head trauma, which is critical for preventing secondary brain injuries. The device is versatile and finds applications in various settings, including hospitals, military operations, remote screenings, sports medicine, pediatrics, and ambulance services. InfraScan, founded in 2004, collaborates with distributors across North America, South America, Africa, Asia, the Middle East, and Europe to reach a wide market. The company's innovative approach was pioneered by a team of researchers and has undergone extensive clinical testing, positioning InfraScan as a leader in the realm of emergency diagnostic tools.

NuPathe Inc., a Pennsylvania-based specialty pharmaceutical company, specializes in developing and commercializing branded therapeutics for neurological and psychiatric disorders. Its primary product, Zecuity, is a transdermal patch used for acute migraine treatment. NuPathe's pipeline includes NP201, a long-acting treatment for Parkinson's disease, and NP202, a long-term solution for schizophrenia and bipolar disorder, both leveraging its biodegradable implant technology. The company, founded in 2005, operates as a subsidiary of Teva Pharmaceutical Industries Limited and is actively seeking partnerships to expand its global reach.

Formae, Inc. is a company specializing in joint resurfacing technology, focusing on the development of innovative products for arthroscopic joint resurfacing and replacement. Founded in 2006 and based in Paoli, Pennsylvania, Formae has created a proprietary synthetic cartilage used in its biocompatible implant, known as ArthroPad. This implant provides a minimally invasive surgical option for replacing damaged cartilage in arthritic joints, addressing conditions such as arthritis and joint destruction. Through its advanced technology, Formae aims to improve patient outcomes in joint care.

Phoenix S&T, Inc. is a developer and supplier of advanced nanospray and microspray systems tailored for life science research and drug discovery. Founded in 2001, the company specializes in the design and production of micro-molded devices, including its Nimbus and pneu-Nimbus NanoLC systems, which facilitate ionization for various applications such as proteomics, biomarker analysis, and clinical diagnostics. Phoenix S&T's product offerings also include column heaters, column coolers, emitters, and 3D microfluidic devices, all engineered for seamless integration with existing mass spectrometers and high-throughput robotics. The company serves a diverse clientele across Europe and China, positioning itself as a key player in the fields of drug discovery and homeland security. With headquarters located in Chadds Ford, Pennsylvania, Phoenix S&T continues to innovate in the realm of microfluidics and analytical technology.

Melior Discovery, Inc. is a biotechnology company based in Exton, Pennsylvania, specializing in developing an in vivo pharmacology platform aimed at identifying novel therapeutic applications for pre-clinical and development-stage drug candidates. Founded in 2005, the company utilizes its innovative theraTRACE indications discovery platform, which systematically evaluates a single compound across multiple in vivo models. This approach enables Melior to assess the potential utility of drug candidates in various therapeutic areas, including neurodegenerative diseases, inflammation, pain management, metabolic disorders, gastrointestinal issues, cardiovascular diseases, and dermatology. Melior Discovery primarily serves clients in the pharmaceutical and biopharmaceutical industries, offering rapid and cost-effective solutions for identifying new therapeutic potentials of existing drugs.

Avid Radiopharmaceuticals is a Philadelphia-based company focused on the development of molecular imaging agents designed to enhance the medical management of chronic diseases. Its mission centers on creating innovative imaging compounds that facilitate the early identification of pathological changes, thereby supporting earlier diagnosis and improved management of various conditions. Avid's notable product, Amyvid, is an imaging tool utilized in positron emission tomography to detect beta-amyloid plaques in the brain, which plays a crucial role in the assessment of Alzheimer's disease. Through its advancements in molecular imaging, Avid aims to contribute to the development of new therapies and improve clinical outcomes for patients suffering from significant chronic illnesses.

Jenrin Discovery develops small-molecule therapeutics for chronic diseases, with a focus on peripherally selective agents targeting peripheral tissues. Its research encompasses obesity, diabetes, NAFLD/NASH, and autoimmune/inflammatory disorders, aiming to improve efficacy and safety for metabolic and inflammatory conditions. Founded in 2004, the company is headquartered in Philadelphia, Pennsylvania.

StageMark develops and markets inflammatory diseases identification and monitoring solutions. The company's product, CB-CAPs, enables user to analyze complement products bound to various blood cell types such as erythrocytes, platelets, reticulocytes, and lymphocytes. StageMark, Inc. was founded in 2004 and is headquartered in Pittsburgh, Pennsylvania.

NuPathe Inc., a Pennsylvania-based specialty pharmaceutical company, specializes in developing and commercializing branded therapeutics for neurological and psychiatric disorders. Its primary product, Zecuity, is a transdermal patch used for acute migraine treatment. NuPathe's pipeline includes NP201, a long-acting treatment for Parkinson's disease, and NP202, a long-term solution for schizophrenia and bipolar disorder, both leveraging its biodegradable implant technology. The company, founded in 2005, operates as a subsidiary of Teva Pharmaceutical Industries Limited and is actively seeking partnerships to expand its global reach.

Avid Radiopharmaceuticals is a Philadelphia-based company focused on the development of molecular imaging agents designed to enhance the medical management of chronic diseases. Its mission centers on creating innovative imaging compounds that facilitate the early identification of pathological changes, thereby supporting earlier diagnosis and improved management of various conditions. Avid's notable product, Amyvid, is an imaging tool utilized in positron emission tomography to detect beta-amyloid plaques in the brain, which plays a crucial role in the assessment of Alzheimer's disease. Through its advancements in molecular imaging, Avid aims to contribute to the development of new therapies and improve clinical outcomes for patients suffering from significant chronic illnesses.

NuPathe Inc., a Pennsylvania-based specialty pharmaceutical company, specializes in developing and commercializing branded therapeutics for neurological and psychiatric disorders. Its primary product, Zecuity, is a transdermal patch used for acute migraine treatment. NuPathe's pipeline includes NP201, a long-acting treatment for Parkinson's disease, and NP202, a long-term solution for schizophrenia and bipolar disorder, both leveraging its biodegradable implant technology. The company, founded in 2005, operates as a subsidiary of Teva Pharmaceutical Industries Limited and is actively seeking partnerships to expand its global reach.

InfraScan, Inc. is a Philadelphia-based medical device company specializing in the development and commercialization of hand-held diagnostic devices that utilize near-infrared (NIR) technology for assessing head injuries and strokes. The company’s primary product, the Infrascanner, allows clinicians to accurately detect intracranial bleeding in patients experiencing head trauma, which is critical for preventing secondary brain injuries. The device is versatile and finds applications in various settings, including hospitals, military operations, remote screenings, sports medicine, pediatrics, and ambulance services. InfraScan, founded in 2004, collaborates with distributors across North America, South America, Africa, Asia, the Middle East, and Europe to reach a wide market. The company's innovative approach was pioneered by a team of researchers and has undergone extensive clinical testing, positioning InfraScan as a leader in the realm of emergency diagnostic tools.